<DOC>
	<DOCNO>NCT00753662</DOCNO>
	<brief_summary>The primary objective trial ass ability Transcranial Magnetic Stimulation H2 coil prefrontal parieto-temporal cortex improve cognitive performance patient Alzheimer 's disease receive drug treatment . This study single-center , double-blind 4 month duration trial .</brief_summary>
	<brief_title>Deep Transcranial Magnetic Stimulation Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>Primary outcome measure : ADAS-COG ( time frame baseline , 2 month , 4 month ) Secondary outcome measure : CGI-C , Neuropsychological computerize test ( Mindstream ) , FAB , ADL , Beck Depression Inventory-time frame baseline,1 month ( visit 12 ) 2 month ( visit 16 ) , 4 month ( visit 17 ) . Estimated enrollment : 45 patient Estimated Study start Date : November 2008 Estimated Study Completion date : November 2012 Number arm : 3 Interventions detail : H2 coil device Transcranial Magnetic Stimulation MAGSTIM prefrontal parieto-temporal region bilaterally frequency 10Hz one arm , 1Hz second arm , sham-stimulation frequency 10Hz/1Hz third arm . Ages : 50-80 Genders :</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Written inform consent obtain diagnostic evidence probable AD consistent DSM IV stable treatment AcetylcholineEsterase Inhibitors or/and Memantine 5 week prior screen stable dose treatment drug MMSE &lt; 25 Patients neurological psychiatric disorder affect cognition distinguishable AD Patients unwilling unable fulfill requirement study Severe personality disorder Malignant untreated Hypertension History Epilepsy History Head trauma Metal implant head , cardiac pacemaker , medical pump Drug alcohol addiction Involvement clinical trial precede 3 month Patient unwilling unable give Informed Consent</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>TMS AD H2 coil</keyword>
</DOC>